Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030
New and Events...
Abiant Selected to Present at 2009 Human Amyloid Imaging Conference
Deerfield, ILLINOIS - - April 24, 2009 - - Work co-authored by members of Abiant and the New York University School of Medicine was presented on April 24 at the 2009 Human Amyloid Imaging (HAI) Meeting in Seattle, Washington. The presentation, titled "Combining Amyloid Imaging and Measurement of Regional Cerebral Glucose Metabolism to Evaluate Dementia State and Progression", focused on the results of analyses performed using two different types of imaging scans on participants in the Alzheimers Disease Neuroimaging Initiative (ADNI).
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the ADNI website.
Further information from the HAI Meeting can be found at HAI Meeting Notes provided by the Alzheimers Forum.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers of drug effects and disease progression. The imaging information, which includes biochemical, functional, and structural measurements, is intended to accelerate or reduce risk of decision making in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,” "achieve," and "enable." There are a number of important factors that could cause Abiant's results to differ materially from those indicated by these forward-looking statements.